ANAB Latest Headlines

Wedbush Keeps Their Buy Rating on AnaptysBio (ANAB)

at www.tipranks.com (Fri, 28-Feb 8:45 AM)

Wall Street Analysts Are Bullish on Top Healthcare Picks

at www.tipranks.com (Fri, 28-Feb 8:30 AM)

Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions

at www.tipranks.com (Fri, 28-Feb 6:38 AM)

AnaptysBio Reports Strong Progress in Clinical Trials

at www.tipranks.com (Fri, 28-Feb 12:06 AM)

AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst

at www.tipranks.com (Thu, 27-Feb 9:15 PM)

AnaptysBio GAAP EPS of -$0.72 beats by $0.91, revenue of $43.11M

at seekingalpha.com (Thu, 27-Feb 4:52 PM)

AnaptysBio’s Promising Prospects Highlighted by Recent Data: A Buy Recommendation by David Risinger

at www.tipranks.com (Sun, 23-Feb 10:25 AM)